DEM BioPharma is a Massachusetts-based biotechnology company that develops and commercializes immunotherapeutics for the treatment of cancer. They are pioneering the next generation of immunotherapeutics designed to unleash macrophages and other myeloid effector cells to eliminate tumors by targeting novel ‘don’t eat me’ (DEM) and ‘eat me’ (EM) signals on cancer cells and macrophages. Their proprietary CHoMP™ platform (Co-culture with Human Myeloid Phagocytes) will be used to develop a pipeline of products that target the tumor microenvironment.
However, their primary competitors include Turnstone Biologics, ImmunityBio, Immatics and 26 more.
Location: United States, Massachusetts, Cambridge
Member count: 1-10
Total raised: $70M
Founded date: 2022
Investors 3
| Date | Name | Website |
| 31.12.2022 | Alta Partn... | altapartne... |
| - | DC Investm... | dcinvestme... |
| 25.06.2022 | Insight Pa... | insightpar... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 24.06.2022 | Series A | $70M | Alta Partn... | - |